Skip to main content
. Author manuscript; available in PMC: 2014 Apr 3.
Published in final edited form as: Sci Transl Med. 2013 Apr 3;5(179):179ra43. doi: 10.1126/scitranslmed.3005265

Figure 4. Effects of low-dose IL-2 on Treg and Tcon in vivo.

Figure 4

(A) Concentrations of plasma IL-2 and absolute numbers of Treg during IL-2 therapy. Median values for 14 patients are shown. (B) Concentrations of plasma IL-7 and IL-15 during IL-2 therapy. Median values for 14 patients are shown. (C) Representative flow cytometry histograms for identification of Ki-67+ proliferating cells in Treg and Tcon subsets. Percentage of Ki-67+ cells is shown for each histogram. (D) Percentage of Ki-67+ proliferating cells in Treg and Tcon subsets during IL-2 therapy (median values). *Treg vs. Tcon (p < 0.001, Wilcoxon-signed-rank test). (E) Recent thymic emigrants (CD45RA+CD31+) within Treg and Tcon subsets during IL-2 therapy. Median fold changes are shown for each subset. *Treg vs. Tcon (p < 0.005, Wilcoxon-signed-rank test). (F) Levels of intracellular Bcl-2 in Treg and Tcon subsets during IL-2 therapy. Median % increase in mean fluorescence intensity is shown. *Treg vs. Tcon (p < 0.05, Wilcoxon-signed-rank test).